CompletedPhase 2NCT00454363
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
Studying Gastroenteric neuroendocrine neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- James YaoM.D. Anderson Cancer Center
- Intervention
- Laboratory Biomarker Analysis(other)
- Enrollment
- 52 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2007 – 2014
Study locations (3)
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- M D Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00454363 on ClinicalTrials.govOther trials for Gastroenteric neuroendocrine neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07161882ALG-LungCancerRegistry (SAFRO2202)Société Algérienne de Formation et de Recherche en Oncologie
- ACTIVE NOT RECRUITINGPHASE2NCT03110978Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung CancerM.D. Anderson Cancer Center